GLP-1 Medication Brands Ozempic lawsuit and settlement cases potentially being investigated include claims involving individuals who suffered from gastroparesis, stomach problems or other injury (such as vision loss, deep vein thrombosis or pulmonary embolisms) after taking Ozempic and/or other GLP-1 medications to treat diabetes and/or obesity, including: Ozempic (semaglutide) Mounjaro (tirzepatide) Wegovy (semaglutide) Rybelsus (semaglutide) Trulicity (dulaglutide) Zepbound (tirzepatide) Saxenda (liraglutide) Other GLP-1 agonist medications Other diabetes or weight loss drug lawsuit cases Diabetics, weight loss patients and other individuals who were diagnosed with gastroparesis (stomach paralysis) or suffered other injury (e.g., vision loss, deep vein thrombosis, pulmonary embolism, etc.) after taking Ozempic, Mounjaro, Wegovy and/or other GLP-1 receptor agonist medications may qualify
If you do not remember until the following day, skip the missed dose - do not take two doses together to make up for a forgotten dose
Hypoglycaemia risk is generally low with GLP-1 agonists when used as monotherapy, as their glucose-lowering effect is glucose-dependent
Rehydrate and revitalize with our Signature Nutrient Blend
TreeFam: 2008 update
A 2003 randomized trial found 500 mcg of sublingual cobalamin as effective as an oral dose for restoring B12 status, including in deficient patients
